Claims for Patent: 8,741,291

Summary for Patent: 8,741,291

Title:	Multifunctional antibody conjugates
Abstract:	The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.
Inventor(s):	Bhat; Abhijit Suresh (Encinitas, CA), Bradshaw; Curt William (San Diego, CA), Laurent; Olivier Alexandre (San Diego, CA), Lee; Alice (Poway, CA), Preston; Richard Ryan (Escondido, CA), Tumelty; David (San Diego, CA), Wood; Lauren Diane (San Diego, CA), Yu; Wei Hong (San Diego, CA)
Assignee:	Covx Technologies Ireland, Limited (Dun Laoghaire County, Dublin, IE)
Application Number:	13/305,354
Patent Claims:	1. A composition comprising a multifunctional antibody conjugate (MAC), the MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00114## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof, wherein the MAC is prepared by covalently attaching the Effector Moiety to a linker terminating in an activated ester with a leaving group Z* of the formula: ##STR00115## where R.sup.1 is F, and h=3, 4 or 5, and reacting the Effector Moiety-Linker-Z* complex so formed with the antibody, wherein at least about 50% of the Effector Moiety in the composition or sample is conjugated to K188-CLK. 2. The composition as claimed in claim 1, further comprising H.sup.18[9]-CL.kappa.. 3. The composition as claimed in claim 1, further comprising D.sup.151-CL.kappa.. 4. The composition as claimed in claim 1, wherein the CL.kappa. region comprises at least residues 62-103 of SEQ ID NO:15, SEQ ID NO:45, SEQ ID NO:46, or SEQ ID NO:47. 5. The composition as claimed in claim 1, wherein the CL.kappa. region comprises at least residues 1-106 of SEQ ID NO: 15, SEQ ID NO:45, SEQ ID NO:46, or SEQ ID NO:47. 6. The composition as claimed in claim 1, wherein the Effector Moiety is only conjugated to the MAC at K.sup.188 CL.kappa.. 7. The composition as claimed in claim 1, wherein the Effector Moiety is conjugated to the MAC at K.sup.188 CL.kappa. on at least one light chain, and at one other location on the antibody. 8. The composition as claimed in claim 1, wherein the Effector Moiety is conjugated to CL.kappa. K.sup.188 on both light chains. 9. The composition as claimed in claim 1, wherein the Effector Moiety is conjugated to CL.kappa. K.sup.188 on one light chain only. 10. The composition as claimed in claim 1, wherein the Effector Moiety is a therapeutic agent, protein, peptide, nucleic acid, aptamer, small molecule, protein agonist, protein antagonist, metabolic regulator, hormone, toxin, growth factor, or diagnostic agent, such that when the at least one Effector Moiety is a protein or peptide, the X group of the linker is covalently attached to the amino terminus, carboxyl terminus, or side chain of a peptide-linking residue in the protein or peptide, and wherein said peptide-linking residue may be selected from the group consisting of K, R, C, T, Y, S, Dap, Dab, K(SH), and homologs of K and C. 11. The composition as claimed in claim 1, wherein Y, X-Y, Y-Z, or X-Y-Z is selected from the group consisting of: ##STR00116## ##STR00117## wherein m, n and j are each independently a range whose lower limits are selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20, and whose upper limit is selected from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30, and wherein the overall length of the linker does not exceed 200 atoms. 12. The composition as claimed in claim 11, wherein the overall length of the linker does not exceed 60 atoms. 13. The composition as claimed in claim 1, wherein the antibody is selected from the group consisting of, Rituximab, Cetuximab, Infliximab, Adalimumab, Natalizumab, Omalizumab, Ranibizumab, Palivizumab, aldolase catalytic antibodies, and full length Fab, Fab', F(ab')2, Fv, dsFv, scFv, VH, diabody, or minibody versions thereof. 14. The MAC as claimed in claim 1, wherein the antibody comprises or SEQ ID NO:3 & SEQ ID NO:4, or SEQ ID NO:51 & SEQ ID NO:52, or SEQ ID NO:53 & SEQ ID NO:54, or a HC region comprising SEQ ID NO:5, a VH region comprising SEQ ID NO:6, a VL region comprising SEQ ID NO:16, and a CL region comprising one of SEQ ID NO:15, SEQ ID NO:45, SEQ ID NO:46 or SEQ ID NO:47. 15. The MAC as claimed in claim 1, wherein the Effector Moiety is an Ang2 binding peptide, and may be selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32. 16. The MAC as claimed in claim 15, comprising the structure: ##STR00118## wherein K.sup.188-CL.kappa. is a covalent link to the side chain of the said K.sup.188-CL.kappa., and the antibody comprises SEQ ID NO:3 and SEQ ID NO:4. 17. The composition as claimed in claim 1, wherein at least about 80% of the Effector Moiety in the composition or sample is conjugated to K.sup.188-CL.kappa.. 18. A composition comprising the MAC as claimed in claim 1, wherein at least about 50% of the antibody comprises an Effector Moiety covalently attached to K.sup.188-CL.kappa.. 19. The composition as claimed in claim 18, wherein at least about 80% of the antibody comprises an Effector Moiety covalently attached to K.sup.188-CL.kappa.. 20. The composition comprising the MAC as claimed in claim 1, wherein at least about 70% of the heavy chain molecules are unconjugated with the Effector Moiety. 21. The composition comprising the MAC as claimed in claim 1, wherein the average number of conjugations per antibody is between about 0.5 and about 1.5. 22. The composition comprising the MAC as claimed in claim 1, wherein the average number of conjugations per antibody is between about 1.5 and about 2.5. 23. A method for preparing a Multifunctional Antibody Conjugate (MAC), said MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; and (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00119## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof, said method comprising a conjugation reaction comprising covalently attaching the Effector Moiety to a linker terminating in a leaving group Z* of the formula: ##STR00120## where R1 is F or Cl, h=2, 3, 4 or 5 and reacting the Effector Moiety-Linker-Z* complex so formed with the antibody. 24. The method as claimed in claim 23, wherein Z* is selected from the group consisting of: ##STR00121## 25. The method as claimed in claim 24, wherein h=4 or 5. 26. The method as claimed in claim 25, wherein Z* is of the formula: ##STR00122## 27. The method as claimed in claim 23, wherein the ratio of Effector Moiety:antibody is between about 1:1 to about 15:1. 28. The method as claimed in claim 23, wherein the ratio is between about 3:1 to about 6:1. 29. The method as claimed in claim 23, wherein the antibody concentration during the conjugation reaction is between about 1 and about 100 mg/ml. 30. The method as claimed in claim 23, wherein the reaction takes place at a pH of between about 6.5 and about 8. 31. A pharmaceutical composition comprising the MAC as claimed in claim 1, and further comprising an acceptable carrier. 32. The pharmaceutical composition as claimed in claim 31, further comprising one or more compounds selected from the group consisting of 5-fluorouracil, irinotecan, oxilaplatin, cetuximab, sunitinib, and rituximab. 33. A method of inhibiting or reducing angiogenesis or treating or preventing a disease or symptom associated with an angiogenic disorder comprising administering to a patient a therapeutically effective dose of a pharmaceutical composition as claimed in claim 32, wherein said angiogenic disorder may be selected from the group consisting of cancers of the lung (NSCLC and SCLC), the head or neck, the ovary, the colon, the rectum, the prostate, the anal region, the stomach, the breast, the kidney or ureter, the renal pelvis, the thyroid gland, the bladder, the brain, renal cell carcinoma, carcinoma of, neoplasms of the central nervous system (CNS), primary CNS lymphoma, non-Hodgkins's lymphoma, spinal axis tumours, carcinomas of the, oropharynx, hypopharynx, esophagus, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract; or lymphoma, lung cancer (NSCLC and SCLC), breast cancer, ovarian cancer, colon cancer, rectal cancer, prostate cancer, cancer of the anal region or a combination of one or more of the foregoing cancers. 34. The composition as claimed in claim 1, wherein at least about 60% of the Effector Moiety in the composition or sample is conjugated to K.sup.188-CL.kappa.. 35. The composition as claimed in claim 1, wherein at least about 70% of the Effector Moiety in the composition or sample is conjugated to K.sup.188-CL.kappa.. 36. A composition comprising a multifunctional antibody conjugate (MAC), the MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00123## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof and wherein at least about 50% of the Effector Moiety in the composition or sample is conjugated to K.sup.188-CL.kappa.. 37. The composition comprising the MAC as claimed in claim 36, wherein at least about 60% of the antibody comprises an Effector Moiety covalently attached to K.sup.188-CL.kappa.. 38. The composition comprising the MAC as claimed in claim 36, wherein at least about 70% of the antibody comprises an Effector Moiety covalently attached to K.sup.188-CL.kappa.. 39. The composition comprising the MAC as claimed in claim 36, wherein at least about 80% of the antibody comprises an Effector Moiety covalently attached to K.sup.188-CL.kappa.. 40. A composition comprising a multifunctional antibody conjugate (MAC), the MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00124## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof, and wherein at least about 70% of the heavy chain molecules are unconjugated with the Effector Moiety. 41. A composition comprising a multifunctional antibody conjugate (MAC), the MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00125## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof, wherein the average number of conjugations per antibody is between about 0.5 and about 1.5, wherein at least about 50% of the Effector Moiety in the composition or sample is conjugated to K188-CLK. 42. A composition comprising a multifunctional antibody conjugate (MAC), the MAC comprising (i) an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL.kappa.) comprising K.sup.188 according to Kabat numbering; (ii) a linker comprising the formula X-Y-Z, wherein Z is a group of formula ##STR00126## and is covalently connected to the antibody through the .epsilon.-amino group of the side chain of K.sup.188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof, wherein the average number of conjugations per antibody is between about 1.5 and about 2.5, wherein at least about 50% of the Effector Moiety in the composition or sample is conjugated to K188-CLK.

Details for Patent 8,741,291

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-07-12
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-07-12
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2030-07-12